Page 266 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 266
Viral Hepatitis: Hepatitis C - Clinical (Therapy) (Cont.)
P0841 SUCCESSFUL COMMUNITY BASED TREATMENT OF
HEPATITIS C IN PEOPLE WHO INJECT DRUGS
Amanda J. Wade*, Diana Macdonald, Joseph S. Doyle,
Alexander J. Thompson, Stuart K. Roberts, Margaret E. Hellard,
Australia
P0842 MALACHITE-I: PHASE 3B TRIAL OF OMBITASVIR/
PARITAPREVIR/R AND DASABUVIR +/-RIBAVIRIN
OR TELAPREVIR + PEGINTERFERON/RIBAVIRIN IN
TREATMENT-NAÏVE ADULTS WITH HCV GENOTYPE 1
Brian Conway*, Ewa Janczewska,Yan Luo, Manuela Curescu,
Susan Greenbloom, Adrian Streinu-Cercel, Florin A. Caruntu,
Wayne Ghesquiere, Brygida Knysz, Włodzimierz Mazur,
Francisco Fuster, Adriana Motoc, Alejandro Soza, Victoria Arama,
Olav Dalgard, Danielle Sullivan, Xuan Liu, Thomas Podsadecki, Canada
P0843 ON-TREATMENT VIRAL KINETICS DO NOT PREDICT SVR
IN PATIENTS WITH ADVANCED LIVER DISEASE RECEIVING
ePOSTERS SOFOSBUVIR IN COMBINATION WITH DACLATASVIR OR
SIMEPREVIR FOR 12 WEEKS
Christophe Hezode*, Stephane Chevaliez, Giovanna Scoazec,
Magali Bouvier-Alias, Isaac Ruiz, Murielle Francois, Ariane Mallat,
Cyrille Feray, Jean-Michel Pawlotsky, France
P0844 IS DUAL INTERFERON AND RIBAVIRIN TREATMENT SAFE
AND EFFICACIOUS AMONG THE CUPIC COHORT -
A RETROSPECTIVE COHORT STUDY
Daniel Schmidt-Martin*, Omar El-Sherif, Orla Crosbie, Susan Corbett,
Susan McKiernan, Suzanne Norris, Ireland
P0845 COMPARATIVE STUDY ON THE EFFECTIVENESS OF
SIMEPREVIR OR TELAPREVIR IN COMBINATION WITH
PEGINTERFERON AND RIBAVIRIN FOR CHRONIC HCV
GENOTYPE 1B INFECTION
Eiichi Ogawa*, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura,
Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh,
Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi,
Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Japan
266 The International Liver Congress™ 2015 • ILC Programme
P0841 SUCCESSFUL COMMUNITY BASED TREATMENT OF
HEPATITIS C IN PEOPLE WHO INJECT DRUGS
Amanda J. Wade*, Diana Macdonald, Joseph S. Doyle,
Alexander J. Thompson, Stuart K. Roberts, Margaret E. Hellard,
Australia
P0842 MALACHITE-I: PHASE 3B TRIAL OF OMBITASVIR/
PARITAPREVIR/R AND DASABUVIR +/-RIBAVIRIN
OR TELAPREVIR + PEGINTERFERON/RIBAVIRIN IN
TREATMENT-NAÏVE ADULTS WITH HCV GENOTYPE 1
Brian Conway*, Ewa Janczewska,Yan Luo, Manuela Curescu,
Susan Greenbloom, Adrian Streinu-Cercel, Florin A. Caruntu,
Wayne Ghesquiere, Brygida Knysz, Włodzimierz Mazur,
Francisco Fuster, Adriana Motoc, Alejandro Soza, Victoria Arama,
Olav Dalgard, Danielle Sullivan, Xuan Liu, Thomas Podsadecki, Canada
P0843 ON-TREATMENT VIRAL KINETICS DO NOT PREDICT SVR
IN PATIENTS WITH ADVANCED LIVER DISEASE RECEIVING
ePOSTERS SOFOSBUVIR IN COMBINATION WITH DACLATASVIR OR
SIMEPREVIR FOR 12 WEEKS
Christophe Hezode*, Stephane Chevaliez, Giovanna Scoazec,
Magali Bouvier-Alias, Isaac Ruiz, Murielle Francois, Ariane Mallat,
Cyrille Feray, Jean-Michel Pawlotsky, France
P0844 IS DUAL INTERFERON AND RIBAVIRIN TREATMENT SAFE
AND EFFICACIOUS AMONG THE CUPIC COHORT -
A RETROSPECTIVE COHORT STUDY
Daniel Schmidt-Martin*, Omar El-Sherif, Orla Crosbie, Susan Corbett,
Susan McKiernan, Suzanne Norris, Ireland
P0845 COMPARATIVE STUDY ON THE EFFECTIVENESS OF
SIMEPREVIR OR TELAPREVIR IN COMBINATION WITH
PEGINTERFERON AND RIBAVIRIN FOR CHRONIC HCV
GENOTYPE 1B INFECTION
Eiichi Ogawa*, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura,
Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh,
Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi,
Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Japan
266 The International Liver Congress™ 2015 • ILC Programme
